Lack of evidence for the selection of E138 mutations by first-generation non-nucleoside reverse transcriptase inhibitors in patients infected with HIV-1 non-B subtypes

被引：1
作者：
Abecasis, Ana B. [1 ,2 ]
van Laethem, Kristel [3 ,4 ]
Theys, Kristof [4 ]
机构：
[1] Univ Nova Lisboa, Global Heath & Trop Med, P-1200 Lisbon, Portugal
[2] Univ Nova Lisboa, Inst Higiene & Med Trop, Unidade Saude Publ Int & Bioestat, P-1200 Lisbon, Portugal
[3] Univ Hosp Leuven, AIDS Reference Lab, Louvain, Belgium
[4] KU Leuven Univ Leuven, Dept Microbiol & Immunol, Rega Inst Med Res Clin & Epidemiol Virol, Leuven, Belgium
来源：
AIDS | 2015年 / 29卷 / 08期
关键词：
VIROLOGICAL FAILURE; RESISTANCE; THERAPY;
D O I：
10.1097/QAD.0000000000000627
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：987 / 988
页数：2
相关论文
共 16 条
[1]   Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes [J].
Crawford, Keith W. .
AIDS, 2014, 28 (15) :2331-2332
[2]   Occurrence of etravirine/rilpivirine-specific resistance mutations selected by efavirenz and nevirapine in Kenyan patients with non-B HIV-1 subtypes failing antiretroviral therapy [J].
Crawford, Keith W. ;
Njeru, Dorothy ;
Maswai, Jonah ;
Omondi, Milton ;
Apollo, Duncan ;
Kimetto, Jane ;
Gitonga, Lawrence ;
Munyao, James ;
Langat, Raphael ;
Aoko, Appolonia ;
Tarus, Jemutai ;
Khamadi, Samoel ;
Hamm, Tiffany E. .
AIDS, 2014, 28 (03) :442-445
[3]   Naturally Selected Rilpivirine-Resistant HIV-1 Variants by Host Cellular Immunity [J].
Gatanaga, Hiroyuki ;
Murakoshi, Hayato ;
Hachiya, Atsuko ;
Hayashida, Tsunefusa ;
Chikata, Takayuki ;
Ode, Hirotaka ;
Tsuchiya, Kiyoto ;
Sugiura, Wataru ;
Takiguchi, Masafumi ;
Oka, Shinichi .
CLINICAL INFECTIOUS DISEASES, 2013, 57 (07) :1051-1055
[4]   Real-life rilpivirine resistance and potential emergence of an E138A-positive HIV strain in north-eastern France [J].
Jeulin, H. ;
Foissac, M. ;
Boyer, L. ;
Agrinier, N. ;
Perrier, P. ;
Kennel, A. ;
Velay, A. ;
Goehringer, F. ;
Henard, S. ;
Rabaud, C. ;
May, T. ;
Schvoerer, E. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (11) :3095-3102
[5]   Web resources for HIV type 1 genotypic-resistance test interpretation [J].
Liu, TF ;
Shafer, RW .
CLINICAL INFECTIOUS DISEASES, 2006, 42 (11) :1608-1618
[6]   HIV-1 genetic variation and drug resistance development [J].
Megens, Sarah ;
Van Laethem, Kristel .
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2013, 11 (11) :1159-1178
[7]   Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing [J].
Melikian, George L. ;
Rhee, Soo-Yon ;
Varghese, Vici ;
Porter, Danielle ;
White, Kirsten ;
Taylor, Jonathan ;
Towner, William ;
Troia, Paolo ;
Burack, Jeffrey ;
DeJesus, Edwin ;
Robbins, Gregory K. ;
Razzeca, Kristin ;
Kagan, Ron ;
Liu, Tommy F. ;
Fessel, W. Jeffrey ;
Israelski, Dennis ;
Shafer, Robert W. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (01) :12-20
[8]   Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure:: a randomized trial [J].
Meynard, JL ;
Vray, M ;
Morand-Joubert, L ;
Race, E ;
Descamps, D ;
Peytavin, G ;
Matheron, S ;
Lamotte, C ;
Guiramand, S ;
Costagliola, D ;
Brun-Vézinet, F ;
Clavel, F ;
Girard, PM .
AIDS, 2002, 16 (05) :727-736
[9]   Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138 [J].
Pelemans, H ;
Aertsen, A ;
Van Laethem, K ;
Vandamme, AM ;
De Clercq, E ;
Pérez-Pérez, MJ ;
San-Félix, A ;
Velázquez, S ;
Camarasa, MJ ;
Balzarini, J .
VIROLOGY, 2001, 280 (01) :97-106
[10]   HIV-1 pol mutation frequency by subtype and treatment experience:: extension of the HIVseq program to seven non-B subtypes [J].
Rhee, SY ;
Kantor, R ;
Katzenstein, DA ;
Camacho, R ;
Morris, L ;
Sirivichayakul, S ;
Jorgensen, L ;
Brigido, LF ;
Schapiro, JM ;
Shafer, RW .
AIDS, 2006, 20 (05) :643-651
12